Evidence map›Paper›PMID 40293691›Full record

ArticleAnnals of nuclear medicine2025

Validation study on accuracy of our newly proposed methods for post-therapeutic liver reserve capacity estimation utilizing

Kana Yamazaki, Tatsuya Higashi, Ryuichi Nishii, Tamasa Terada, Yoichi Mizutani, Yuki Ogura, Mana Akamatsu, Toshitaka Kuroiwa, Hirokazu Makishima, Masaru Wakatsuki and 1 more

Abstract readValidation Study
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kana YamazakiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4‑9‑1 Anagawa, Inage‑ku, Chiba, Chiba, 263‑8555, Japan.
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4‑9‑1 Anagawa, Inage‑ku, Chiba, Chiba, 263‑8555, Japan. higashi.tatsuya@qst.go.jp.ORCID http://orcid.org/0000-0002-8338-4737
Ryuichi NishiiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4‑9‑1 Anagawa, Inage‑ku, Chiba, Chiba, 263‑8555, Japan.
Tamasa TeradaDepartment of Radiology, Faculty of Medicine, University of Miyazaki, Miyazaki, Miyazaki, Japan.
Yoichi MizutaniDepartment of Radiology, Nishinokyo Hospital, Nara, Nara, Japan.
Yuki OguraDepartment of Medical Technology, QST Hospital, National Institutes for Quantum Science and Technology (QST), Chiba, Chiba, Japan.
Mana AkamatsuDepartment of Medical Technology, QST Hospital, National Institutes for Quantum Science and Technology (QST), Chiba, Chiba, Japan.
Toshitaka KuroiwaDepartment of Medical Technology, QST Hospital, National Institutes for Quantum Science and Technology (QST), Chiba, Chiba, Japan.
Hirokazu MakishimaQST Hospital, National Institutes for Quantum Science and Technology (QST), Chiba, Chiba, Japan.
Masaru WakatsukiQST Hospital, National Institutes for Quantum Science and Technology (QST), Chiba, Chiba, Japan.
Hitoshi IshikawaQST Hospital, National Institutes for Quantum Science and Technology (QST), Chiba, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCarbon-ion radiotherapy (CIRT) is known as a promising treatment for liver tumors. However, no method has been established for estimating post-therapeutic residual liver reserve capacity (pRLRC). We previously introduced the estimation method of pRLRC using

methodsPatients who received CIRT for liver tumors in our hospital and underwent

resultsGSA-RL, Validation 1 and 2 were calculated as 0.448 ± 0.214, 0.413 ± 0.199 and 0.435 ± 0.208 mg/min, respectively. Post-GSA-Rmax was 0.428 ± 0.220 mg/min. The relationship between post-GSA-Rmax and each parameter was y = 0.02 + 0.90x (R

conclusionsThe estimation of pRLRC by Yamazaki method and Yamazaki-variant was in good agreement with post-therapeutic liver reserve capacity after CIRT, and there was no difference in the accuracy of the estimation. The usefulness of Yamazaki method, which is simpler and more clinically applicable, was confirmed.

trial registrationThis study is registered in UMIN Clinical Trials Registry (UMIN-CTR) as UMIN study ID: UMIN000038328 and UMIN000049770, UMIN000038174.

Indexed as

Heavy Ion RadiotherapyLiverLiver NeoplasmsTechnetium Tc 99m Aggregated AlbuminTechnetium Tc 99m PentetateAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadionuclide ImagingTechnetium Tc 99m Aggregated Albumintechnetium Tc 99m DTPA-galactosyl-human serum albuminTechnetium Tc 99m Pentetate99mTc-GSA scintigraphyCarbon-ion radiotherapyDose distributionGSA-RLGSA-RmaxLiver tumor

Identifiers

PMID40293691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.